Article citationsMore>>

M. Ychou, C. Astre, P. Rouanet, J. M. Fabre, B. SaintAubert, J. Domergue, et al., “A Phase II Study of 5-Fluorouracil, Leucovorin and Cisplatin (FLP) for Metastatic Gastric Cancer,” European Journal of Cancer, Vol. 32A, No. 11, 1996, pp. 1933-1937. doi:10.1016/0959-8049(96)00147-5

has been cited by the following article:

• TITLE: Dose-Dense Regimen of Cisplatin and Infusional Fluorouracil in Advanced Gastric Cancer—A Single Institution Experience

  AUTHORS: Ofer Purim, Yulia Kundel, Roni Shapira, Baruch Brenner

  KEYWORDS: Gastric Cancer; Dose-Dense; Cisplatin; Fluorouracil

  JOURNAL NAME: Journal of Cancer Therapy, Vol.4 No.2, April 15, 2013

  ABSTRACT: Chemotherapy with continuous infusion of 5-fluorouracil and cisplatin in a monthly schedule is one of the most common regimens in the treatment of advanced gastric cancer. In this study, we evaluated the efficacy and safety of a dosedense administration of this regimen in this patient population. Sixty-six consecutive patients with previously untreated histologically confirmed unresectable or metastatic gastric adenocarcinoma were treated with a 2-hour infusion of cisplatin 100 mg/m2 followed by continuous infusion of 5-fluorouracil 1000 mg/m2/day for 5 days, every 21 days. The most common grade ≥3 toxicities were fatigue (42%), nausea/vomiting (30%) and leucopenia (12%). Four patients (6%) died from treatment-related toxicity. The response rate was 35%, the median progression-free survival was 4.3 months and the median survival was 5.9 months. In light of these results, the dose-dense approach seems to offer little, if any, benefit compared with the standard regimens.